Manitoba health officials are looking at options for expanding capacity for health facilities if the COVID-19 outbreak continues to accelerate in the province.
They announced eight more probable cases of COVID-19 bringing the total to 72, Dr. Brent Roussin, chief provincial public health officer, announced on Sunday.
There were no new deaths reported while two people have fully recovered while there is one individual admitted to intensive care and one more admitted to hospital.
Public Health investigations are continuing into if the cases are travel related or connected to other cases.
“We know that this virus is spread through droplets in the air … from sympotomatic individuals and from close contact with them,” said Roussin. “If we limit our close contact with others, then we are not going to be able to spread that virus to others.”
Several other provinces are currently looking at what spaces within municipalities can be used to take on more beds for patients, including schools and recreation centres which are largely sitting vacant now due to the virus.
Manitoba has yet to make any similar announcements but did Lanette Siragusa, provincial lead, health system integration, quality and chief nursing officer for Shared Health said they are looking at options, to at least provide opportunities for people to self-isolate if they do not have one.
“As part of our planning processes we are looking at different settings where we could expand capacity if we need to,” she said. “The majority of COVID-19 patients are OK in the community, most of them won’t need to go to the hospital, but they do need a safe place to isolate and get through that 14-day period.”
The Cadham Provincial Lab has completed 7,147 total tests as of Friday, while there were 919 tests performed on Friday.
The province is now working on a way to better measure the spread of the coronavirus so they can track any potential flattening of the curve. The more data they collect the better they will be able to model it.
“Those total numbers can only go up, so that’s not the only indication as to how we are doing against this virus,” said Roussin.
The updated orders to the Provincial Health Act go live at 12:01 a.m. on Monday and they drop the limit of the size of groups from 50 to 10 in any indoor or outdoor location.
The incoming changes did not stop people from taking advantage of the weather on Sunday and flooding local parks.
Roussin cautioned against this, saying people need to maintain social distancing protocols wherever they are.
“We’re going to have thing in place to respond to such things,” said Roussin. “If you’re getting out to a park and you notice there are crowds starting, you need to turn back. This is not the time to ignore our social distancing strategies.”
The province also put out a call to Manitobans to take part in clinical trials for the drug Hydroxychloroquine through the University of Manitoba’s Rady Faculty of Health Sciences. The drug has been used to treat and prevent malaria since the 1950s.
“Typically you need large numbers, this is part of a multi-centre trial, so Manitobans will be linking into other centres that are running the trial,” said Roussin.
'Truly sorry': Scientists pull panned Lancet study of Trump-touted drug – National Post
NEW YORK/LONDON — An influential study that found hydroxychloroquine increased the risk of death in COVID-19 patients has been withdrawn a week after it led to major trials being halted, adding to confusion about a malaria drug championed by U.S. President Donald Trump.
The Lancet medical journal pulled the study after three of its authors retracted it, citing concerns about the quality and veracity of data in it. The World Health Organization (WHO) will resume its hydroxychloroquine trials after pausing them in the wake of the study. Dozens of other trials have resumed or are in process.
The three authors said Surgisphere, the company that provided the data, would not transfer the dataset for an independent review and they “can no longer vouch for the veracity of the primary data sources.”
The fourth author of the study, Dr. Sapan Desai, chief executive of Surgisphere, declined to comment on the retraction.
The Lancet said it “takes issues of scientific integrity extremely seriously” adding: “There are many outstanding questions about Surgisphere and the data that were allegedly included in this study.”
Another study in the New England Journal of Medicine (NEJM) that used Surgisphere data and shared the same lead author, Harvard Medical School Professor Mandeep Mehra, was retracted for the same reason.
The Lancet said reviews of Surgisphere’s research collaborations were urgently needed.
The race to understand and treat the new coronavirus causing the COVID-19 pandemic has accelerated the pace of research and peer-reviewed scientific journals are go-to sources of information for doctors, policymakers and lay people alike.
Chris Chambers, a professor of psychology and an expert at the UK Center for Open Science, said The Lancet and the NEJM – which he described as “ostensibly two of the world’s most prestigious medical journals” – should investigate how the studies got through peer review and editorial checks.
“The failure to resolve such basic concerns about the data” raises “serious questions about the standard of editing” and about the process of peer review, he said.
The Lancet did not immediately respond to a Reuters request for comment. The NEJM could not immediately be reached for comment.
The observational study published in The Lancet on May 22 said it looked at 96,000 hospitalized COVID-19 patients, some treated with the decades-old malaria drug. It claimed that those treated with hydroxychloroquine or the related chloroquine had higher risk of death and heart rhythm problems than patients who were not given the medicines.
“I did not do enough to ensure that the data source was appropriate for this use,” the study’s lead author, Professor Mehra, said in a statement. “For that, and for all the disruptions – both directly and indirectly – I am truly sorry.”
Many scientists voiced concern about the study, which had already been corrected last week because some location data was wrong. Nearly 150 doctors signed an open letter to The Lancet calling the article’s conclusions into question and asking to make public the peer review comments that preceded publication.
Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine said the retraction decision was “correct” but still left unanswered the question about whether hydroxychloroquine is effective in COVID-19.
“It remains the case that the results from randomized trials are necessary to draw reliable conclusions,” he said. (Reporting by Michael Erman, Peter Henderson, Kate Kelland and Josephine Mason Editing by Leslie Adler, Tom Brown, Giles Elgood and Carmel Crimmins)
Possible link between more overdoses and pandemic isolation: Guelph health officials – CTV News
The number of suspect overdose deaths in Guelph since the outbreak of COVID-19 has already surpassed the number of deaths in all of 2019.
Health officials say isolation could be a contributing factor, as staff at the consumption treatment centre have seen about half of the regular users during the time of the pandemic.
“From mid March until just the end of May we’ve seen eight deaths,” said Raechelle Devereaux, executive director of the Guelph Community Health Centre.
In 2018, there were seven overdose deaths in Guelph.
Jade McAfee uses the CTS site and say she’s lost a lot of friends to overdoses.
“It is scary,” she said. “I myself have overdosed 13 times.”
While officials say a toxic supply is to blame for overdoses, the COVID-19 pandemic has added a hurdle when it comes to prevention.
“The same things that are keeping people safe during the pandemic like isolating and staying home are some things that work against us,” said Devereaux.
Registered nurse Danielle Castledine supervises injections and says they would normally see 30 people a day before the pandemic.
“Before we had an intermediate space where people could be before and after,” she said. “So even if they were waiting they were waiting with peer workers and nurses and social workers.”
To help with better spacing, they’ve opened a new booth to decrease wait times and encourage more people to use the services.
“[Before the crisis] you didn’t have to have a mask, get stopped, have your temperature taken when you could blow in and out easily,” said Eric Cunningham, a user of the CTS site.
Staff say the lack of foot traffic at the CTS is a bad sign and worry the alternative is using in isolation, which decreases the likelihood of potentially life-saving intervention.
“It’s better for anybody to not do it alone,” said McAfee.
The health centre says between March 17 and May 30 there were 63 overdoses.
In the same time period last year there were 74, but only one overdose death.
The Guelph Community Health Centre says the team is door knocking at vulnerable apartment and shelters to give more information on harm reduction to help those potential using alone.
Unmasking the stealth virus behind COVID-19 – CBC.ca
Scientists have discovered the pandemic-causing coronavirus is unique in short-circuiting the safest way our immune system kills off a virus, which could have implications for treating COVID-19 with interferon.
Interferon describes a family of proteins produced by the body’s immune system in response to an invading viral infection. As the name implies, interferon interferes with the virus’s ability to copy itself.
Interferon drugs are made in the lab and were used for years to treat hepatitis, a liver infection, as well as other diseases that involve the immune system, such as multiple sclerosis and some cancers.
In May, researchers in Hong Kong published the results of their Phase 2 trial on fewer than 150 people who were admitted to hospital with mild or moderate COVID-19. Participants were randomly assigned to a combination of potential antivirals, including interferon, or placebo injections for two weeks.
The findings lent support to the idea of continuing research efforts, including in Canada, to investigate interferon in larger, blinded trials designed to find more definitive answers.
Dr. Jordan Feld, a liver specialist at Toronto General Hospital and senior scientist at U of T, previously used interferon to treat people infected with hepatitis. He’s now leading a Phase 2 clinical trial to test a targeted form of the drug, called peginterferon lambda, in injections compared with saline placebo injections.
“It’s kind of like a stealth virus,” Feld said of SARS-CoV-2, the virus that causes COVID-19.
Normally, when interferon in the body’s white blood cells responds to a viral invader, the interferon sends out a flare signal so nearby cells will work to stop the virus from copying itself or replicating if they, too, should be invaded.
In ferrets infected in the lab (a common animal model for studying respiratory viruses), healthy human lung cells, and in people with COVID-19, doctors and scientists say it seems like the natural interferon “flies under the radar” of the immune system and isn’t activated the way it should be.
Feld said the idea behind giving interferon medications is to provide the body with what it should be making to fend off the infection.
The potential therapeutic approach gained scientific backing last month when a study published in the journal Cell showed a “striking” feature of SARS-CoV-2 infection.
Ben tenOever is a Canadian-born professor of microbiology at the Icahn School of Medicine at Mount Sinai in New York who led the Cell study and has been flooded with e-mail requests from researchers the world over to test experimental drug compounds against the virus.
TenOever said every cell that gets infected has two major jobs:
- Fortify its defences and those around it with a “call to arms” mediated by interferon, like sending out an emergency flare for the immune system’s first responders.
- Send a “call for reinforcements” for a longer-term response by releasing proteins called chemokines.
Most viruses block both of those roles.
What makes SARS-Cov-2 unique is it blocks the call-to-arms function from interferon only.
Reinforce call to arms with drug?
“Treatment with interferon or drugs that induce interferon, the main character in the call to arms, is probably beneficial,” tenOever said.
“The secret is to do it early,” he said, when people have a mild cough and test positive for the virus and haven’t developed respiratory distress.
But there could also be mild side-effects.
When we’re fighting off a flu virus, blame interferon for feeling so crummy, feverish and achy as your immune system kicks into high gear.
Likewise, interferon drugs, could also lead to flu-like symptoms for a day or two.
Individuals enrolling in COVID-19 clinical trials of interferon based in Toronto, Hamilton, Ont., Harvard in Cambridge, Mass., Stanford in California, Johns Hopkins in Baltimore and elsewhere will need to weigh whether that (potential) shortfall is worth the (potential) payoff of protection from the deadly damage and delivers key answers that only their participation can offer.
TenOever said what the enormous scientific interest in the publication shows is an incredible demand for biosafety Level 3 labs like his during the pandemic. Without that lab capacity, the fear is that medical researchers won’t be able to run all the experiments they need to do to guide vaccine efforts.
Matthew Miller is an associate professor of infectious disease and immunology at McMaster University who isn’t involved in the clinical trials or studies.
Miller said interferon is what cells use to try to kill off the virus by themselves.
“Its sort of the preferred route,” Miller said, adding interferon is also the safest way for the body to get rid of a virus.
Miller called tenOever’s paper “an important first step in understanding how our body is responding to this particular new virus.”
Speed up recovery
Dr. Sarah Shalhoub, a transplant infectious disease physician at Western University’s medical school, studied the use of interferon to treat another coronavirus infection called Middle East Respiratory Syndrome or MERS.
While interferon hasn’t yet panned out to fight MERS, Shalhoub is optimistic for COVID-19.
“Patients that received interferon beta clear their viruses faster and the duration for hospital admission was also significantly lower,” Shalhoub said of the Hong Kong findings last month.
“It was encouraging in that sense that there might be an effective therapy that’s available on the market that can be repurposed.”
Shalhoub was quick to add a caution. Since no one in either the drug or placebo group died, the mild infections and response to them are difficult to interpret without more research.
China grows 'more assertive' in world politics as the U.S. leaves behind a vacuum, ex-diplomat says – CNBC
Should everyone be tested for COVID-19? Most Canadians think so, poll shows – CTV News
Toronto FC captain says Donald Trump doesn't have 'a moral bone in his body' – CP24 Toronto's Breaking News
- Sports13 hours ago
NBA Board of Governors approves competitive format to restart 2019-20 season with 22 teams returning to play – NBA CA
- Economy24 hours ago
Higgs calls for 'cultural shift' to turn N.B.'s economic fortunes around – CBC.ca
- Tech21 hours ago
Successful investors are using big data and machine learning—now you can, too – Financial Post
- Media22 hours ago
Police Chief responds to controversy over social media posts – Quinte News
- Science20 hours ago
The Strawberry Moon Eclipse May Be Visible Over Metro Vancouver This Week – 604 Now
- Art23 hours ago
Dan Fumano: Questions, shock as art studio's death blamed on COVID-19 – Brockville Recorder and Times
- Tech23 hours ago
Apple tracks looters who steal iPhones – BBC News
- Tech22 hours ago
Sonos Arc is available to buy in Canada on June 10th – MobileSyrup